DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas

References

1. 1.↵
   1. Ostrom QT,
   2. Gittleman H,
   3. Liao P, et al

   . CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 2017;19:v1–88 doi:10.1093/neuonc/nox158 pmid:29117289

   CrossRefPubMed
2. 2.↵
   1. Tian W,
   2. Liu J,
   3. Zhao K, et al

   . Analysis of prognostic factors of World Health Organization grade III meningiomas. Front Oncol 2020;10:593073 doi:10.3389/fonc.2020.593073 pmid:33425743

   CrossRefPubMed
3. 3.↵
   1. Durand A,
   2. Labrousse F,
   3. Jouvet A, et al

   . WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 2009;95:367–75 doi:10.1007/s11060-009-9934-0 pmid:19562258

   CrossRefPubMed
4. 4.↵
   1. Masalha W,
   2. Heiland DH,
   3. Delev D, et al

   . Survival and prognostic predictors of anaplastic meningiomas. World Neurosurg 2019;131:e321–28 doi:10.1016/j.wneu.2019.07.148 pmid:31356972

   CrossRefPubMed
5. 5.↵
   1. Harter PN,
   2. Braun Y,
   3. Plate KH

   . Classification of meningiomas-advances and controversies. Chin Clin Oncol 2017;6(Suppl 1):S2 doi:10.21037/cco.2017.05.02 pmid:28595423

   CrossRefPubMed
6. 6.↵
   1. Kunz WG,
   2. Jungblut LM,
   3. Kazmierczak PM, et al

   . Improved detection of transosseous meningiomas using 68 Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 2017;58:1580–87 doi:10.2967/jnumed.117.191932 pmid:28450556

   Abstract/FREE Full Text
7. 7.↵
   1. Ivanidze J,
   2. Roytman M,
   3. Lin E, et al

   . Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging 2019;29:650–56 doi:10.1111/jon.12632 pmid:31107591

   CrossRefPubMed
8. 8.↵
   1. Mizutani G,
   2. Nakanishi Y,
   3. Watanabe N, et al

   . Expression of somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem 2012;45:167–76 doi:10.1267/ahc.12006 pmid:22829710

   CrossRefPubMed
9. 9.↵
   1. Huang RY,
   2. Bi WL,
   3. Weller M, et al

   . Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 2019;21:26–36 doi:10.1093/neuonc/noy137 pmid:30137421

   CrossRefPubMed
10. 10.↵
    1. Kim SH,
    2. Roytman M,
    3. Madera G, et al

    . Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep 2022;12:9256 doi:10.1038/s41598-022-13467-9 pmid:35661809

    CrossRefPubMed
11. 11.↵
    1. Hoffman S,
    2. Propp JM,
    3. McCarthy BJ

    . Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006;8:27–37 doi:10.1215/S1522851705000323 pmid:16443945

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Okano A,
    2. Miyawaki S,
    3. Teranishi Y, et al

    . Advances in molecular biological and translational studies in World Health Organization grades 2 and 3 meningiomas: a literature review. Neurol Med Chir (Tokyo) 2022;62:347–60 doi:10.2176/jns-nmc.2022-0114

    CrossRefPubMed
13. 13.↵
    1. Zhang P,
    2. Yu J,
    3. Li J, et al

    . Clinical and prognostic value of PET/CT imaging with combination of 68 Ga-DOTATATE and 18 F-FDG in gastroenteropancreatic neuroendocrine neoplasms. Contrast Media Mol Imaging 2018;2018:2340389 doi:10.1155/2018/2340389 pmid:29681780

    CrossRefPubMed
14. 14.↵
    1. Günther T,
    2. Tulipano G,
    3. Dournaud P, et al

    . International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 2018;70:763–835 doi:10.1124/pr.117.015388 pmid:30232095

    Abstract/FREE Full Text
15. 15.↵
    1. Vasilaki A,
    2. Thermos K

    . Somatostatin analogues as therapeutics in retinal disease. Pharmacol Ther 2009;122:324–33 doi:10.1016/j.pharmthera.2009.03.010 pmid:19351548

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Bassant MH,
    2. Simon A,
    3. Poindessous-Jazat F, et al

    . Medial septal GABAergic neurons express the somatostatin sst2A receptor: functional consequences on unit firing and hippocampal theta. J Neurosci 2005;25:2032–41 doi:10.1523/JNEUROSCI.4619-04.2005 pmid:15728843

    Abstract/FREE Full Text
17. 17.↵
    1. Barresi V,
    2. Alafaci C,
    3. Salpietro F, et al

    . Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep 2008;20:485–92 pmid:18695896

    PubMedWeb of Science
18. 18.↵
    1. de Oliveira Silva CB,
    2. Ongaratti BR,
    3. Trott G, et al

    . Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol 2015;8:13185–92 pmid:26722517

    PubMed
19. 19.↵
    1. Seystahl K,
    2. Stoecklein V,
    3. Schüller U, et al

    . Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 2016;18:1538–47 doi:10.1093/neuonc/now060 pmid:27106404

    CrossRefPubMed
20. 20.↵
    1. Sommerauer M,
    2. Burkhardt JK,
    3. Frontzek K, et al

    . 68 Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol 2016;18:1021–27 doi:10.1093/neuonc/now001 pmid:26865086

    CrossRefPubMed
21. 21.↵
    1. Roytman M,
    2. Kim S,
    3. Glynn S, et al

    . PET/MR imaging of somatostatin receptor expression and tumor vascularity in meningioma: implications for pathophysiology and tumor outcomes. Front Oncol 2021;11:820287 doi:10.3389/fonc.2021.820287 pmid:35155210

    CrossRefPubMed
22. 22.↵
    1. Laudicella R,
    2. Albano D,
    3. Annunziata S, et al

    . Theragnostic use of radiolabelled dota-peptides in meningioma: from clinical demand to future applications. Cancers (Basel) 2019;11:1412 doi:10.3390/cancers11101412 pmid:31546734

    CrossRefPubMed
23. 23.↵
    1. Van Essen M,
    2. Kenning EP,
    3. Kooij PP, et al

    . Effects of therapy with [177 Lu-DOTA 0, Tyr 3] octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599–606 pmid:17015894

    Abstract/FREE Full Text
24. 24.↵
    1. Moazzam AA,
    2. Wagle N,
    3. Zada G

    . Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus 2013;35:E18 doi:10.3171/2013.10.FOCUS13341 pmid:24289126

    CrossRefPubMed
25. 25.↵
    1. Roytman M,
    2. Pisapia DJ,
    3. Liechty B, et al

    . Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging 2020;66:18–22 doi:10.1016/j.clinimag.2020.04.026 pmid:32442855

    CrossRefPubMed